For over two decades, the VIVA Foundation has focused on bridging scientific discovery and patient care through its signature multidisciplinary approach. The upcoming event integrates The VEINS—which targets venous endovascular strategies—with VIVA’s broader scope of interventional cardiology, radiology, and vascular surgery. This year’s agenda emphasizes real-world registries and randomized controlled trials, addressing conditions ranging from pulmonary embolism to chronic limb-threatening ischemia.
In section Releases
VIVA and The VEINS 2026 to Unveil 26 Late-Breaking Vascular Trials
Twenty-six clinical trials will headline the joint VIVA and The VEINS 2026 conferences, scheduled for October 3–6 at the Bellagio Las Vegas. The event serves as a global stage for the latest data in peripheral vascular disease and venous intervention, offering physicians early access to research shaping future clinical standards.
Key presentations include the 24-month results of the NIH-sponsored C-TRACT trial regarding iliac vein stent placement, as well as the 12-month outcomes of the SELUTION4SFA trial comparing sirolimus-eluting balloons to standard angioplasty. Other notable sessions will cover the RAPID-PE study on thrombolysis for intermediate-risk pulmonary embolism and the PROMISE III trial examining transcatheter arterialization of deep veins. By combining live procedural case studies with these late-breaking data releases, the organizers aim to provide a comprehensive view of how current technological innovations are modifying standard practice.
Comments (0)
No comments yet. Be the first!